This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alere™ MobileLink Receives FDA Clearance

WALTHAM, Mass., Aug. 5, 2013 /PRNewswire/ -- Alere™ Connect (an Alere Company) has been granted a 510(k) market clearance by the U.S. Food and Drug Administration for the Alere™ MobileLink.  The new product offering is one of Alere's connected device technologies designed to empower patients by allowing self-testing at home and delivering data quickly and seamlessly to clinical systems accessed by their healthcare providers.

Alere™ MobileLink provides a gateway to Alere's Connected Health platform, which offers integrated tools and services that can enhance care and improve outcomes for all patients, whether they are participants in health and wellness or chronic disease management programs.

Initially, the Alere™ MobileLink will be rolled out with the Alere INRatio®2 PT/INR Monitor through Alere™ Home Monitoring, Inc. (AHM) in programs for patients using anticoagulant medications to monitor their INR levels at home.  Available exclusively from AHM, this combination of Alere products and services is especially exciting as it will further differentiate the industry leading Alere programs for anticoagulation management. The Alere™ MobileLink is also FDA-cleared for over-the-counter use with other FDA-cleared devices including blood-pressure monitors, glucose meters and weight scale.

Alere™ MobileLink is the first of Alere™ Connect's cloud-based communication hubs designed to facilitate the seamless flow of actionable, comprehensive diagnostic data across patient, care professionals and electronic medical records. The Alere™ MobileLink recently received CE Mark certification, which will allow the product to be marketed in Europe as well as the US later this year.

Alere™ Connect CEO Kent Dicks, "Our remote monitoring solutions have been validated over the years with innovative healthcare organizations throughout the US.  Our devices are being used to supply patient data directly into the provider's electronic health records system – integration is key.  The Alere Connected Health platform has the ability to connect flexibly with devices and systems regardless of their manufacturer and origin. The platform captures and analyzes data with robust analytics, and then backs it up with comprehensive health management services.  This is what is really exciting and distinguishes Alere as one of the few healthcare companies to offer a true, fully integrated solution that can impact patients' lives for the better."

About Alere™ By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, women's health, infectious disease, oncology and toxicology. Alere is headquartered in Waltham, Massachusetts. For more information regarding Alere please visit

About Alere™ ConnectSince 2006 Alere™ Connect (formerly MedApps®), has developed remote health monitoring solutions that efficiently connect patients with their care providers and electronic health records. Alere Connect is a UL certified company whose regulatory achievements include ISO 13485 / ISO 9001: 2008 certification, CE Mark certification, Health Canada License and multiple FDA clearances. As an acknowledged innovator in the field of remote health monitoring, the company was most recently recognized with a 2011 Edison Award in the product category of Health, Wellness & Safety. For more information, please visit


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs